EP4100514A4 - Durch natürliche oder synthetische dna hergestellte auf poxviren basierende vektoren und deren verwendungen - Google Patents

Durch natürliche oder synthetische dna hergestellte auf poxviren basierende vektoren und deren verwendungen Download PDF

Info

Publication number
EP4100514A4
EP4100514A4 EP21750239.2A EP21750239A EP4100514A4 EP 4100514 A4 EP4100514 A4 EP 4100514A4 EP 21750239 A EP21750239 A EP 21750239A EP 4100514 A4 EP4100514 A4 EP 4100514A4
Authority
EP
European Patent Office
Prior art keywords
natural
synthetic dna
vectors produced
poxvirus vectors
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21750239.2A
Other languages
English (en)
French (fr)
Other versions
EP4100514A2 (de
Inventor
Don J. Diamond
Felix WUSSOW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of EP4100514A2 publication Critical patent/EP4100514A2/de
Publication of EP4100514A4 publication Critical patent/EP4100514A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21750239.2A 2020-02-03 2021-02-02 Durch natürliche oder synthetische dna hergestellte auf poxviren basierende vektoren und deren verwendungen Pending EP4100514A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969628P 2020-02-03 2020-02-03
US202063113803P 2020-11-13 2020-11-13
PCT/US2021/016247 WO2021158565A2 (en) 2020-02-03 2021-02-02 Poxvirus-based vectors produced by natural or synthetic dna and uses thereof

Publications (2)

Publication Number Publication Date
EP4100514A2 EP4100514A2 (de) 2022-12-14
EP4100514A4 true EP4100514A4 (de) 2024-06-12

Family

ID=77200801

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21750239.2A Pending EP4100514A4 (de) 2020-02-03 2021-02-02 Durch natürliche oder synthetische dna hergestellte auf poxviren basierende vektoren und deren verwendungen

Country Status (10)

Country Link
EP (1) EP4100514A4 (de)
JP (1) JP2023512294A (de)
KR (1) KR20220148823A (de)
CN (1) CN115397998A (de)
AU (2) AU2021217073A1 (de)
BR (1) BR112022014738A2 (de)
CA (1) CA3168836A1 (de)
IL (1) IL294926A (de)
MX (1) MX2022009200A (de)
WO (1) WO2021158565A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (de) 2020-02-14 2024-03-27 Geovax, Inc. Impfstoffe und ihre verwendungen zur induktion einer immunantwort gegen sars-cov2
EP4153228A4 (de) 2020-05-17 2024-07-10 City of Hope Synthetische modifizierte coronavirus-impfstoffe auf vaccinia ankara (smva)-basis
JP2024505274A (ja) 2021-02-02 2024-02-05 ゲオバックス インコーポレイテッド ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト
CN115433741A (zh) * 2022-06-23 2022-12-06 广西大学 盖他病毒为载体表达报告蛋白的重组病毒的构建方法
CN118240879A (zh) * 2023-11-01 2024-06-25 上海市重大传染病和生物安全研究院 骨架质粒、重组质粒以及猴痘病毒颗粒和应用
CN119506355B (zh) * 2025-01-15 2025-10-17 中国人民解放军军事科学院军事医学研究院 一种用于重组痘病毒包装的载体系统及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213452A1 (en) * 2018-05-02 2019-11-07 David Evans Synthetic chimeric vaccinia virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213452A1 (en) * 2018-05-02 2019-11-07 David Evans Synthetic chimeric vaccinia virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRANZISKA KUGLER: "Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems", VIROLOGY JOURNAL, vol. 16, no. 1, 9 August 2019 (2019-08-09), GB, XP093158639, ISSN: 1743-422X, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12985-019-1212-y/fulltext.html> DOI: 10.1186/s12985-019-1212-y *
HIDEYUKI NAKANISHI ET AL: "Comparison oftransposition efficiency between linear and circular donor vectors in mammalian cells", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM NL, vol. 154, no. 4, 19 May 2011 (2011-05-19), pages 205 - 208, XP028240752, ISSN: 0168-1656, [retrieved on 20110527], DOI: 10.1016/J.JBIOTEC.2011.05.009 *

Also Published As

Publication number Publication date
WO2021158565A2 (en) 2021-08-12
KR20220148823A (ko) 2022-11-07
IL294926A (en) 2022-09-01
WO2021158565A3 (en) 2021-09-16
BR112022014738A2 (pt) 2022-10-11
AU2021217073A1 (en) 2022-08-18
CN115397998A (zh) 2022-11-25
JP2023512294A (ja) 2023-03-24
MX2022009200A (es) 2023-01-04
AU2025287330A1 (en) 2026-01-22
CA3168836A1 (en) 2021-08-12
EP4100514A2 (de) 2022-12-14

Similar Documents

Publication Publication Date Title
EP4100514A4 (de) Durch natürliche oder synthetische dna hergestellte auf poxviren basierende vektoren und deren verwendungen
EP3914259A4 (de) Rna-editierende oligonukleotide und deren verwendung
EP3914260A4 (de) Rna-editierende oligonukleotide und deren verwendung
EP3852813A4 (de) Lichtbogenbasierte kapside und deren verwendungen
MA49457A (fr) Molécules d&#39;anticorps se liant à cd73 et leurs utilisations
EP4168135A4 (de) Krafttrainingsgerät mit mehrkabelkrafterzeugung
EP4237107A4 (de) Übungssystem
EP4255446A4 (de) Multicistronische rna-impfstoffe und verwendungen davon
EP3794037A4 (de) Anti-claudin-18.2-antikörper und verwendungen dafür
MA51583A (fr) Molécules d&#39;acide nucléique hétéroduplex et leurs utilisations
EP3762031A4 (de) Anti-claudin-18.2-antikörper und verwendungen dafür
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
EP4157885A4 (de) Anti-cldn18.2-antikörper und diagnostische verwendungen davon
EP4222174A4 (de) Gegen menschliches claudin 18.2 gerichtete antikörper und verwendungen davon
EP4200414A4 (de) Zusammensetzungen zur oberflächenamplifikation und verwendungen davon
EP4132969A4 (de) Anti-mesothelin-antigenbindende moleküle und verwendungen davon
EP3966321A4 (de) Asx-spezifische proteinligasen und deren verwendungen
EP4068987A4 (de) Verfahren zur verbesserung des zellwachstums mit speziesspezifischen oder gattungsspezifischen proteinen und deren anwendungen
EP4262750A4 (de) Proteinformulierungen und verwendungen davon
EP3839070A4 (de) Marker im zusammenhang mit der dna-methylierung zur diagnose von tumoren und anwendung davon
EP4352046A4 (de) Isoindolinonverbindungen und verwendungen davon
EP4430614A4 (de) Zirkulierende tumor-dna-fraktion und verwendungen davon
MA55750A (fr) Formulations d&#39;anticorps stables et à faible viscosité et leurs utilisations
EP3843790A4 (de) Nukleinsäurekonstrukte mit geneditierenden multi-sites und verwendungen davon
EP4267609A4 (de) Antikörper gegen menschliches und affen-cd3 und verwendungen davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220803

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

A4 Supplementary search report drawn up and despatched

Effective date: 20240515

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/245 20060101ALI20240508BHEP

Ipc: A61K 39/215 20060101ALI20240508BHEP

Ipc: A61K 39/12 20060101ALI20240508BHEP

Ipc: C12Q 1/68 20180101ALI20240508BHEP

Ipc: C12N 15/863 20060101ALI20240508BHEP

Ipc: C12N 7/02 20060101ALI20240508BHEP

Ipc: C12N 5/10 20060101AFI20240508BHEP